Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial.
By C. Koopmans, D. Bijlenga, H. Groen, S. Vijgen, J. Aarnoudse, D. Bekedam, Paul P. van den Berg, K. de Boer, J. Burggraaff, K. Bloemenkamp and 14 more. The Lancet, 2009
752 citations recorded by the source corpus.
Subfields: Obstetrics and Gynecology, Pediatrics, Perinatology and Child Health
View Paper: https://www.semanticscholar.org/paper/eff6b0f11f0da173fc7a672e1229940775a0a424
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Jimmy Espinoza
- A. Vidaeff
- C. Pettker
- Hyagriv Simhan
Citations in the corpus
- Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. (2020, background): “In addition, no differences in rates of neonatal complications or cesarean delivery were reported by the authors (107).”
- The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. (2021, neutral): “At term ( ≥ 37 + 0 weeks), women with pre-eclampsia should be offered birth based on the results of the HYPITAT trial [181].”
- Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis (2013, neutral): “protocols, others favour expectant monitoring [75, 77].”